Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX   US74365A1016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
05/18/2015 05/19/2015 05/20/2015 05/21/2015 05/22/2015 Date
2.2(c) 2.24(c) 2.24(c) 2.22(c) 2.18(c) Last
95 120 729 831 1 710 307 1 478 022 560 385 Volume
+3.29% +1.82% 0.00% -0.89% -1.80% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 13,0x
Capi. / Sales 2014 5,70x
Capitalization 204 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
Sector
Biotechnology & Medical Research
Calendar
06/04 | 01:00pmPresentation
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
05/14 Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
05/08 PROTALIX BIOTHERAPEUTICS : Reports First Quarter 2015 Financial Results
05/07 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition (form 8..
05/07 Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
03/13 PROTALIX BIOTHERAPEUTICS : Reports Full Year 2014 Financial Results and Provides..
03/12 PROTALIX BIOTHERAPEUTICS : reports 4Q loss
03/12 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition (form 8..
03/12 Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provide..
More news
Sector news : Biotechnology & Medical Research - NEC
05/22 SYNAGEVA BIOPHARMA : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investiga..
05/22 BLUEBIRD BIO : Announces Participation at the Jefferies 2015 Global Healthcare C..
05/21 ABBVIE : specifies breakdown of $21 billion Pharmacyclics deal
More sector news : Biotechnology & Medical Research - NEC
Comments 
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions